Get the Stockscreener App
0.5052
2.49%
-0.0129
Eyenovia Inc stock is traded at $0.5052, with a volume of 355.11K.
It is down -2.49% in the last 24 hours and up +4.66% over the past month.
Eyenovia Inc is a clinical stage ophthalmic company developing a pipeline of therapeutics based on its propriety array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Opejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies which target new indications or new combinations.
See More
Previous Close:
$0.5181
Open:
$0.5026
24h Volume:
355.11K
Relative Volume:
0.23
Market Cap:
$44.03M
Revenue:
-
Net Income/Loss:
$-37.28M
P/E Ratio:
-0.7322
EPS:
-0.69
Net Cash Flow:
$-32.24M
1W Performance:
-8.64%
1M Performance:
+4.66%
6M Performance:
-49.98%
1Y Performance:
-64.67%
1-Day Range:
$0.4925
$0.5321
1-Week Range:
$0.4853
$0.5589
52-Week Range:
$0.37
$2.57
Eyenovia Inc Stock (EYEN) Company Profile
Name
Eyenovia Inc
Sector
Industry
Phone
813-766-9539
Address
295 MADISON AVENUE,, NEW YORK, NY
Eyenovia Inc Stock (EYEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-01-21 | Initiated | Northland Capital | Outperform |
| Feb-03-20 | Downgrade | Oppenheimer | Outperform → Perform |
Eyenovia Inc Stock (EYEN) Latest News
EYEN (Eyenovia) Cash Flow from Operations : $-30.23 Mil (TTM As of Jun. 2024) - GuruFocus.com
Eyenovia reveals Optejet dispenser benefits in study - Investing.com
Eyenovia Announces Publication of Study Demonstrating - GlobeNewswire
Eyenovia reveals Optejet dispenser benefits in study By Investing.com - Investing.com UK
Eyenovia Announces Publication of Study Demonstrating Favorable Impact on the Ocular Surface of Medication Delivered with the Optejet® - StockTitan
Here's Why Eyenovia (EYEN) Is a Great 'Buy the Bottom' Stock Now - MSN
EYENEyenovia, Inc. Latest Stock News & Market Updates - StockTitan
Presbyopia Market on Track for Major Expansion by 2034, According to DelveInsight | Eyenovia, Orasis Pharma, Ocuphire Pharma, Novartis, Visus Therapeutics - The Globe and Mail
Eyenovia Announces Presentation of Phase 3 Clobetasol Study Results at the American Academy of Ophthalmology (AAO) 2024 Expo - The Manila Times
Eyenovia Announces Presentation of Phase 3 Clobetasol Study - GlobeNewswire
Mydriasis Market Forecasted to Surge in Coming Years, 2024-2034 - openPR
Wall Street analysts’ outlook for Eyenovia Inc (EYEN) - SETE News
Monitoring Eyenovia Inc (EYEN) after recent insider movements - Knox Daily
Eyenovia Inc (EYEN) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - Yahoo Finance
Eyenovia Inc’s results are impressive - US Post News
Quarterly Snapshot: Quick and Current Ratios for Eyenovia Inc (EYEN) - The Dwinnex
Eyenovia Inc [EYEN] Records 200-Day SMA of $1.0954 - Knox Daily
Eyenovia begins manufacturing next-gen drug delivery system - Drug Delivery Business News
Top investors say Eyenovia Inc (EYEN) ticks everything they need - SETE News
Eyenovia begins Gen-2 Optejet production for Mydcombi By Investing.com - Investing.com South Africa
Eyenovia begins Gen-2 Optejet production for Mydcombi - Investing.com
Eyenovia Announces Commencement of Manufacturing of its Advanced, Second Generation Optejet Device - The Manila Times
Eyenovia Inc [EYEN] Investment Guide: What You Need to Know - Knox Daily
Is Eyenovia Inc (EYEN) a good investment opportunity? - US Post News
Trading Day Review: Eyenovia Inc (EYEN) Gains Momentum, Closing at 0.50 - The Dwinnex
Eyenovia Announces Share Offering and Warrant Sale for Growth - TipRanks
SEC Form 424B5 filed by Eyenovia Inc. - Quantisnow
Eyenovia stock slides on pricing capital raise of about $4 million via securities offering - MSN
Eyenovia secures $4 million in registered direct offering - Investing.com India
Eyenovia secures $4 million in registered direct offering By Investing.com - Investing.com Canada
Eyenovia, Inc. Announces Pricing of $4 Million Registered Direct Offering - ForexTV.com
Eyenovia Prices of $4 Million Registered Direct Offering - citybiz
Eyenovia Announces U.S. Launch and Commercial Availability of Clobetasol Propionate Ophthalmic Suspension 0.05% for Postoperative Inflammation Following Ocular Surgery - Vision Monday
Eyenovia launches FDA-approved clobetasol for ocular surgery By Investing.com - Investing.com Australia
Eyenovia Inc [EYEN] Shares Rise 2.89 % on Wednesday - Knox Daily
Eyenovia announces commercial availability of clobetasol, shares rise - MSN
Eyenovia Announces Launch and Commercial Availability of Clobetasol Propionate Ophthalmic Suspension 0.05% for Post-Operative Inflammation and Pain Following Ocular Surgery - ForexTV.com
Eyenovia launches FDA-approved clobetasol for ocular surgery - Investing.com
Eyenovia Announces Launch and Commercial Availability of - GlobeNewswire
Stocks of Eyenovia Inc (EYEN) are poised to climb above their peers - SETE News
Analyzing Eyenovia Inc (EYEN) After Recent Trading Activity - Knox Daily
What was Eyenovia Inc (EYEN)’s performance in the last session? - US Post News
Eyenovia Inc (EYEN)’s financial ratios: A comprehensive overview - The Dwinnex
Certain Warrants of Eyenovia, Inc. are subject to a Lock-Up Agreement Ending on 22-SEP-2024. - Marketscreener.com
Eyenovia faces Nasdaq delisting over share price dip By Investing.com - Investing.com Canada
Eyenovia faces Nasdaq delisting over share price dip - Investing.com
Eyenovia Inc [EYEN] Shares Fall -1.59 % on Wednesday - Knox Daily
Eyenovia Inc (EYEN) Stock: A Year of Market Movement, Down and Up - The InvestChronicle
Eyenovia Inc Stock (EYEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Eyenovia Inc Stock (EYEN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Rowe Michael M | Chief Executive Officer |
Aug 26 '24 |
Buy |
0.57 |
50,000 |
28,500 |
82,927 |
| Grant Stuart M. | 10% Owner |
Jul 02 '24 |
Buy |
0.66 |
1,515,151 |
1,000,000 |
10,914,153 |
| Grant Stuart M. | 10% Owner |
Mar 28 '24 |
Buy |
0.98 |
100,000 |
98,000 |
5,430,715 |
| Grant Stuart M. | 10% Owner |
Mar 19 '24 |
Buy |
1.23 |
50,000 |
61,500 |
5,330,715 |
| Grant Stuart M. | 10% Owner |
Mar 08 '24 |
Buy |
1.58 |
10,717 |
16,911 |
5,280,715 |
| Rowe Michael M | Chief Executive Officer |
Dec 04 '23 |
Buy |
1.36 |
4,890 |
6,650 |
32,927 |
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):